Arcellx (ACLX) Capital Expenditures (QoQ) (2021 - 2025)
Arcellx (ACLX) Capital Expenditures (QoQ) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 671.31% |
| Sep 30, 2025 | 145.75% |
| Jun 30, 2025 | -166.41% |
| Mar 31, 2025 | -93.55% |
| Dec 31, 2024 | 245.59% |
| Sep 30, 2024 | -358.67% |
| Jun 30, 2024 | -50.05% |
| Mar 31, 2024 | -54.77% |
| Dec 31, 2023 | 1,519.36% |
| Sep 30, 2023 | -113.86% |
| Jun 30, 2023 | 637.55% |
| Mar 31, 2023 | 188.24% |
| Dec 31, 2022 | 282.80% |
| Sep 30, 2022 | -224.83% |
| Jun 30, 2022 | -68.09% |
| Mar 31, 2022 | -90.17% |
| Dec 31, 2021 | 2,300.46% |
| Sep 30, 2021 | -121.43% |
| Jun 30, 2021 | 323.53% |